Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris(ITN059AI)

Trial Profile

Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris(ITN059AI)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Abatacept (Primary) ; Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PAUSE
  • Most Recent Events

    • 13 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Jun 2015 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018, according to ClinicalTrials.gov record.
    • 05 Jun 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top